Floatz logo

Dilanubicel

Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)

Nohla Therapeutics, Inc.Cell therapyPhase 2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
89/ 100

Competitive context

16 Active assets in the Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) cohort.

Asset / SponsorPhaseRating
Daunorubicin
National Cancer Institute (NCI)
Phase 3BBB
ETOPOSIDE
Alice Mims
Phase 3BBB
Cytosin-Arabinosid
The First Affiliated Hospital of Soochow University
Phase 3BBB
Idarubicine
The First Affiliated Hospital of Soochow University
Phase 2BBB
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-
National Cancer Institute (NCI)
Phase 2BBB

View all 50 →

Same molecule, other indications

Dilanubicel is also rated in:

acute myeloid leukemia, del(5q31-q32)Dormant
CCC
Indicative ·
52 / 100
View asset →
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
CCC
Indicative ·
52 / 100
View asset →
acute myeloid leukemia with 11q23 abnormalitiesDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →